The approval was based on the therapy’s safety and efficacy data, including muscle health and longer-term functional outcomes.

Groundbreaking gene therapy offers hope for a boy with fatal muscular dystrophy, potentially slowing disease progression and ...

The early months of 2025 have seen a surge of research centered on cannabidiol (CBD), with studies investigating its role in ...

Nucleoside reverse transcriptase inhibitors -- antiretroviral drugs approved to treat HIV and hepatitis B -- were associated ...

Capricor Therapeutics CAPR will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for ...

Richard Finkel, MD, a pediatric neurologist at St. Jude Children’s Research Hospital, was included in the Time100 Health list ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Good afternoon, and welcome to the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its ...

Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.86%, which has investors questioning if this is right time to sell.

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

MEDFORD, Ore.- A fundraiser held at the Children’s Museum of Southern Oregon raises thousands of dollars to help a local boy ...

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...